{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-025596","form_type":"8-K","ticker":null,"cik":"0001779020","company_name":"Danimer Scientific, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.493163+00:00","generated_at":"2026-06-04T08:34:18.911749+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Danimer Scientific raises $15M in registered direct offering of common stock and warrants","bullets":["Gross proceeds of $15.0M from sale of 15M shares/equivalents and 15M warrants at $1.00 per unit.","11.25M common shares and 3.75M pre-funded warrants sold; common warrants have $1.33 strike, exercisable in 6 months.","Net proceeds to be used for working capital and general corporate purposes.","Roth Capital Partners acted as exclusive placement agent; 7% cash fee paid.","Company and insiders subject to 90-day lock-up on securities sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-025596","json":"https://secwatch.observer/filing/0001213900-24-025596.json","markdown":"https://secwatch.observer/filing/0001213900-24-025596.md","text":"https://secwatch.observer/filing/0001213900-24-025596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1779020/000121390024025596/0001213900-24-025596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1779020/000121390024025596/ea020246801-8k_danimer.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:34:18.911749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c143ef24fc5ff54ada60b7abf1629047644de92","claim":"Danimer Scientific, Inc. entered into Purchase Agreement with a certain investor valued at aggregate of 11,250,000 shares of Class A common stock, pre-funded warrants for up to 3,750,000 shar (effective 2024-03-20).","evidence_excerpt":"On March 20, 2024, Danimer Scientific, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with a certain investor for the purchase and sale, in a registered direct offering by the Company (the “Registered Offering”), of (i) an aggregate of 11,250,000 shares of its Class A common stock, par value $0.0001 per share (“Common Stock”) (ii) pre-funded warrants to purchase up to an aggregate of 3,750,000 shares of Common Stock (the “Pre-Funded Warrants”) and (iii) accompanying warrants to purchase up to an aggregate of 15,000,000 shares of Common Stock (the “Common Warrants”) at a combined offering price of $1.00 per share of Common Stock and associated Common Warrant, or $0.9999 per Pre-Funded Warrant and associated Common Warrant, resulting in gross proceeds of approximately $15.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1779020/000121390024025596/0001213900-24-025596-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a certain investor"},{"label":"Value","value":"aggregate of 11,250,000 shares of Class A common stock, pre-funded warrants for up to 3,750,000 shar"},{"label":"Effective","value":"2024-03-20"}],"fact_type":"material_agreement"},{"claim_id":"aa8d4d68aaa956e65d7e8402408668918132a275","claim":"Danimer Scientific, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at cash fee of 7% of the aggregate gross proceeds raised in the Registered Offering, plus reimbursement (effective 2024-03-20).","evidence_excerpt":"On March 20, 2024, Danimer Scientific, Inc., (the “Company”), entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with a certain investor for the purchase and sale, in a registered direct offering by the Company (the “Registered Offering”), of (i) an aggregate of 11,250,000 shares of its Class A common stock, par value $0.0001 per share (“Common Stock”) (ii) pre-funded warrants to purchase up to an aggregate of 3,750,000 shares of Common Stock (the “Pre-Funded Warrants”) and (iii) accompanying warrants to purchase up to an aggregate of 15,000,000 shares of Common Stock (the “Common Warrants”) at a combined offering price of $1.00 per share of Common Stock and associated Common Warrant, or $0.9999 per Pre-Funded Warrant and associated Common Warrant, resulting in gross proceeds of approximately $15.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1779020/000121390024025596/0001213900-24-025596-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Roth Capital Partners, LLC"},{"label":"Value","value":"cash fee of 7% of the aggregate gross proceeds raised in the Registered Offering, plus reimbursement"},{"label":"Effective","value":"2024-03-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}